Section 4.3: Differentials in Endocrine and Metabolic Disorders

Differentials in Endocrine and Metabolic Disorders

Endocrine and metabolic disorders present complex diagnostic challenges that require matching pathophysiological clues with lab parameters and patient history. The FNP must master the differentiation of diabetes mellitus types, thyroid dysfunctions, and metabolic syndrome, while integrating safe prescribing principles such as the Beers Criteria for older adults.

1. Diabetes Mellitus: Type 1 vs. Type 2 Differentiation

Accurately diagnosing diabetes and identifying the underlying pathology is essential to determine whether insulin or oral therapies are required.

Diagnostic Criteria (ADA Guidelines)

Diabetes mellitus is diagnosed when any of the following criteria are met (and confirmed on a subsequent day with a repeat test, unless classic symptoms are present):

• Fasting Plasma Glucose (FPG): >=126 mg/dL (7.0 mmol/L) after an 8-hour fast.
• Oral Glucose Tolerance Test (OGTT): 2-hour plasma glucose >=200 mg/dL (11.1 mmol/L) following a 75g anhydrous glucose load.
• Hemoglobin A1c (HbA1c): >=6.5%.
• Random Plasma Glucose: >=200 mg/dL (11.1 mmol/L) in a patient presenting with classic symptoms of hyperglycemia (polyuria, polydipsia, polyphagia, unexplained weight loss) or hyperglycemic crisis.

Differentiating Type 1 vs. Type 2 Diabetes

• Type 1 Diabetes Mellitus (T1DM): Autoimmune destruction of pancreatic beta cells leading to absolute insulin deficiency. Onset is typically in children or young adults. Presentation is abrupt, often manifesting as diabetic ketoacidosis (DKA) with metabolic acidosis, ketonuria, and Kussmaul breathing. Patients are usually thin or normal weight. Diagnostic verification relies on positive autoantibodies (Glutamic Acid Decarboxylase [GAD65] antibodies, Islet Cell Antibodies [ICA], and Insulin Autoantibodies [IAA]) and low or undetectable serum C-peptide levels (which reflect endogenous insulin production).
• Type 2 Diabetes Mellitus (T2DM): Progressive insulin secretory defect alongside peripheral insulin resistance. Onset is typically in adults, though increasing in adolescents due to obesity. Presentation is insidious, often asymptomatic for years. Autoantibodies are negative. Serum C-peptide levels are normal or elevated initially, reflecting compensatory hyperinsulinemia.

2. Thyroid Disorders: Hypothyroidism vs. Hyperthyroidism

Thyroid dysfunction is classified by TSH levels and free hormone concentrations, along with autoantibody testing.

Hypothyroidism

• Primary Hypothyroidism: Hashimoto's thyroiditis is the most common cause, characterized by autoimmune thyroid destruction. Clinical signs include fatigue, weight gain, cold intolerance, dry skin, constipation, bradycardia, goiter, and delayed relaxation of deep tendon reflexes. Labs show elevated TSH with low Free T4. Positive Thyroid Peroxidase (TPO) antibodies are diagnostic.
• Secondary (Central) Hypothyroidism: Caused by pituitary or hypothalamic failure. Labs demonstrate a low or inappropriately normal TSH in the presence of a low Free T4.
• Subclinical Hypothyroidism: Elevated TSH (typically 4.5–10 mIU/L) with a normal Free T4. Treatment is initiated for patients who are pregnant, have a TSH >10 mIU/L, are highly symptomatic, or have positive TPO antibodies.

Hyperthyroidism

• Graves' Disease: Autoimmune disorder where thyroid-stimulating immunoglobulins (TSI) stimulate TSH receptors. Clinical signs include weight loss, heat intolerance, anxiety, hand tremors, palpitations, tachycardia, hyperreflexia, diffuse goiter, and exophthalmos. Labs show a suppressed TSH (<0.1 mIU/L) and elevated Free T4 and Free T3. Positive TSI or TSH-receptor antibodies (TRAb) are diagnostic.
• Subclinical Hyperthyroidism: Suppressed TSH with normal Free T4 and Free T3. It requires monitoring due to the risk of bone loss (osteoporosis) and cardiac arrhythmias (especially atrial fibrillation in older adults).

3. Metabolic Syndrome (NCEP ATP III Criteria)

Metabolic syndrome is a cluster of metabolic risk factors that increase the risk of cardiovascular disease and type 2 diabetes. Diagnosis requires meeting at least three of the following five criteria:

1. Abdominal Obesity: Waist circumference >40 inches (102 cm) in men, or >35 inches (88 cm) in women.
2. Hypertriglyceridemia: Triglycerides >=150 mg/dL (or receiving pharmacological treatment for elevated triglycerides).
3. Low HDL Cholesterol: HDL <40 mg/dL in men, or <50 mg/dL in women (or receiving pharmacological treatment for low HDL).
4. Elevated Blood Pressure: Systolic BP >=130 mmHg OR diastolic BP >=85 mmHg (or receiving pharmacological treatment for hypertension).
5. Impaired Fasting Glucose: Fasting plasma glucose >=100 mg/dL (or receiving pharmacological treatment for elevated glucose).

4. Beers Criteria and Clinical Prescribing Precautions

The American Geriatrics Society (AGS) Beers Criteria identifies medications that are potentially inappropriate for older adults (aged >=65) due to high risk of adverse effects:

• Sliding Scale Insulin: Avoid using short-acting insulins based on reactive sliding scales in the absence of basal/prandial insulin due to an unacceptably high risk of severe hypoglycemia.
• Sulfonylureas: Avoid long-acting sulfonylureas (specifically glyburide) due to active metabolites, prolonged half-life, and high risk of severe, persistent hypoglycemia in older adults.
• Antihypertensives: Avoid alpha-1 blockers (e.g., doxazosin, prazosin) as first-line treatment for hypertension due to high risk of orthostatic hypotension and syncope.
• Antiarrhythmics: Avoid amiodarone as first-line for atrial fibrillation due to its narrow therapeutic index and significant toxicities, including amiodarone-induced thyroiditis (hypothyroidism or hyperthyroidism) and pulmonary fibrosis.